A RANDOMIZED CONTROLLED STUDY OF THE EFFECTIVENESS OF CASUAL VIDEO GAMES IN REDUCING SYMPTOMS OF ANXIETY

Anxiety is a natural reaction to stress. However, when anxiety becomes excessive it can develop into a debilitating disorder. Interventions are needed to ameliorate and prevent the development of anxiety related health disorders. Casual video games (CVGs) are fun, easy to play, spontaneous, and extremely popular. In this randomized controlled study the efficacy of CVGs in reducing symptoms of anxiety in a depressed population was tested by comparing individuals in the experimental group, who were prescribed a CVG to utilize over a one month period, with a no-treatment control group. The methodology included participants in the experimental group playing a CVG three times a week for 30 minutes each session, over a one-month period. The State Trait Anxiety Inventory (STAI) was used to measure participants' state and trait anxiety pre-post intervention. Results from both state and trait measures demonstrated that the intervention was effective in reducing state and trait anxiety symptom severity scores for the experimental group when compared to the control group. These findings demonstrate the use of prescriptive interventions that utilize CVGs as a way to treat anxiety, as well as, implications that include the potential expansion of applications of CVGs as an adjunct to medicine and other medical therapies being utilized alone.  M.S

Active compensation of extrinsic polarization errors using adaptive optics

We present a scheme for active compensation of complex extrinsic polarization perturbations introduced into an optical system. Imaging polarimeter is used to measure the polarization state across a beam profile and a liquid crystal spatial light modulator controls the polarization of the input beam. A sequence of measurements permits determination of the birefringence properties of a perturbing specimen. The necessary correction is calculated and fed back to the polarization modulator to compensate for the polarization perturbation. The system capabilities are demonstrated on a range of birefringent specimens

Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein

High-density lipoprotein (HDL) levels are reduced in patients with coronavirus disease 2019 (COVID-19), and the extent of this reduction is associated with poor clinical outcomes. While lipoproteins are known to play a key role during the life cycle of the hepatitis C virus, their influence on coronavirus (CoV) infections is poorly understood. In this study, we utilize cross-linking mass spectrometry (XL-MS) to determine circulating protein interactors of the severe acute respiratory syndrome (SARS)-CoV-2 spike glycoprotein. XL-MS of plasma isolated from patients with COVID-19 uncovered HDL protein interaction networks, dominated by acute-phase serum amyloid proteins, whereby serum amyloid A2 was shown to bind to apolipoprotein (Apo) D. XL-MS on isolated HDL confirmed ApoD to interact with SARS-CoV-2 spike but not SARS-CoV-1 spike. Other direct interactions of SARS-CoV-2 spike upon HDL included ApoA1 and ApoC3. The interaction between ApoD and spike was further validated in cells using immunoprecipitation-MS, which uncovered a novel interaction between both ApoD and spike with membrane-associated progesterone receptor component 1. Mechanistically, XL-MS coupled with data-driven structural modeling determined that ApoD may interact within the receptor-binding domain of the spike. However, ApoD overexpression in multiple cell-based assays had no effect upon viral replication or infectivity. Thus, SARS-CoV-2 spike can bind to apolipoproteins on HDL, but these interactions do not appear to alter infectivity.</p

A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma

Diffuse midline gliomas (DMGs) are devastating pediatric brain tumors recognized as the leading cause of cancer-related death in children. DMGs are high-grade gliomas (HGGs) diagnosed along the brain's midline. Euchromatin is the hallmark feature of DMG, caused by global hypomethylation of H3K27 either through point mutations in histone H3 genes (H3K27M), or by overexpression of the enhancer of zeste homolog inhibitory protein (EZHIP). In a clinical trial for adults with progressive HGGs, a 22-year-old patient with a thalamic H3K27-altered DMG, showed remarkable clinical and radiological responses to dordaviprone (ONC201). This response in a H3K27-altered HGG patient, coupled with the lack of response of patients harboring wildtype-H3 tumors, has increased the clinical interest in dordaviprone for the treatment of DMG. Additional reports of clinical benefit have emerged, but research defining mechanisms of action (MOA) fall behind dordaviprone's clinical use, with biomarkers of response unresolved. Here, we summarize dordaviprone's safety, interrogate its preclinical MOA- identifying the mitochondrial protease 'ClpP' as a biomarker of response, and discuss other ClpP-agonists, expanding the arsenal of potential weapons in the fight against DMG. Finally, we discuss combination strategies including ClpP-agonists, and its immunomodulatory effects suggestive of a role for the tumor microenvironment in DMG patients' response